Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 31, Number 12—December 2025
Research Letter
Macrolide-Resistant Mycoplasma pneumoniae in Children, Ohio, USA
Table
Mycoplasma pneumoniae testing volume, number of positive tests, sequencing volume, resistance detection, and azithromycin prescriptions, by month, Ohio, USA, September 2023–May 2025*
| Month | Total cohort |
Urgent care center cohort |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No. samples tested | No. (%) positive | No. (%) sequenced | No. (%) resistant | No. samples tested | No. (%) positive | No. (%) sequenced | No. (%) resistant | Azithromycin prescription rate† |
|||
| 2023 | |||||||||||
| Sep | 818 | 5 (0.6) | 0 | NA | 38 | 0 | 0 | NA | 4 | ||
| Oct | 1,001 | 29 (2.9) | 0 | NA | 55 | 6 (10.9) | 0 | NA | 6 | ||
| Nov | 1,348 | 59 (4.4) | 0 | NA | 102 | 7 (6.9) | 0 | NA | 8 | ||
| Dec |
1,697 |
62(3.7) |
0 |
NA |
160 |
13 (8.1) |
0 |
NA |
9 |
||
| 2024 | |||||||||||
| Jan | 1,388 | 57 (4.1) | 6 (10.5) | 0 | 79 | 13 (16.5) | 5 (38.5) | 0 | 6 | ||
| Feb | 1,303 | 29 (2.3) | 6 (20.7) | 0 | 76 | 4 (5.3) | 2 (50.0) | 0 | 5 | ||
| Mar | 1,085 | 45 (4.2) | 1 (2.2) | 0 | 62 | 12 (19.4) | 1 (8.3) | 0 | 5 | ||
| Apr | 965 | 56 (5.8) | 27 (48.2) | 0 | 73 | 14 (19.2) | 10 (71.4) | 0 | 6 | ||
| May | 1,045 | 106 (10.1) | 47 (44.3) | 0 | 130 | 36 (27.7) | 21 (58.3) | 0 | 8 | ||
| Jun | 1,020 | 266 (28.1) | 145 (54.1) | 1 (0.7) | 251 | 126 (50.2) | 82 (65.1) | 1 (1.2) | 25 | ||
| Jul | 1,318 | 407 (30.9) | 226 (55.5) | 2 (0.9) | 396 | 194 (48.7) | 124 (64.3) | 2 (1.6) | 35 | ||
| Aug | 2,009 | 642 (32.0) | 285 (44.4) | 10 (3.9) | 761 | 343 (45.1) | 180 (52.5) | 4 (2.2) | 51 | ||
| Sep | 3,067 | 860 (28.0) | 252 (29.3) | 11 (4.4) | 1,253 | 479 (38.2) | 133 (27.8) | 3 (3.0) | 69 | ||
| Oct | 5,657 | 1,831 (32.4) | 299 (16.3) | 26 (8.7) | 2,084 | 826 (39.6) | 108 (13.1) | 6 (5.6) | 109 | ||
| Nov | 6,943 | 1,649 (23.8) | 276 (16.7) | 13 (4.7) | 2,322 | 693 (29.8) | 117 (16.9) | 3 (2.6) | 131 | ||
| Dec |
6,210 |
1,288 (20.7) |
270 (21.0) |
17 (6.3) |
1,976 |
572 (29.0) |
120 (21.0) |
6 (5.0) |
109 |
||
| 2025 | |||||||||||
| Jan | 2,779 | 388 (14.0) | 121 (31.2) | 8 (6.6) | 587 | 146 (24.9) | 56 (38.4) | 2 (3.5) | 37 | ||
| Feb | 2,032 | 118 (5.8) | 27 (22.9) | 2 (7.4) | 300 | 36 (12.0) | 3 (8.3) | 1 (33.3) | 13 | ||
| Mar | 1,452 | 38 (2.6) | 14 (36.8) | 0 | 174 | 20 (11.5) | 9 (45.0) | 0 | 6 | ||
| Apr | 1,257 | 26 (2.1) | 8 (30.8) | 0 | 132 | 2 (1.5) | 2 (100) | 0 | 6 | ||
| May |
926 |
8 (0.9) |
4 (50.0) |
0 |
131 |
4 (3.1) |
2 (50.0) |
0 |
7 |
||
| Total | 45,320 | 7,969 (17.6) | 2,014 (25.3) | 90 (4.5) | 11,142 | 3,545 (31.8) | 975 (27.5) | 28 (2.9) | |||
*NA, not available. †Per 1,000 patients.
Page created: December 11, 2025
Page updated: December 24, 2025
Page reviewed: December 24, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.